Abstract 18P
Background
Compared to sequential conventional fractionation schedule, Simultaneous integrated Boost provides increased dose homogeneity, with less unintended excessive dose outside the boost area; in combination with a higher dose per fraction to the tumour bed, resulting in a shorter overall treatment time spanning over 5 1⁄2 weeks. We compared cosmesis using the Harvard cosmesis scale and dosimetry of SIB IMRT versus sequential electron boost in breast cancer patients.
Methods
Patients in our Institute who have undergone breast-conserving surgery and received adjuvant chemotherapy, who are referred for adjuvant radiotherapy. The study period spanned from 1st May 2016 to 31st March 2018.
Results
The baseline Harvard score for grading breast cosmesis in both the arms was excellent (84% in SIB and 81% in SEB) or good(16% in SIB and 19% in SEB). None of the patients in either arm had fair or poor cosmesis. Assessment of cosmesis at the end of radiation therapy showed a dip from excellent to good and fair in both the arms ( 34% versus 9% with excellent cosmesis, 53% versus 72% with good cosmesis and 13% versus 19% with poor cosmesis in SIB versus SEB arms) but the patients in the SEB arm had comparatively much lower cosmetic score. However, this difference was not statistically significant(p=0.045). Overall cosmesis at the end of 3 months was better in SIB arm compared to that of the SEB arm and was statistically significant (93% with excellent and good cosmesis in SIB vs 65% in SEB p<0.001). At 6 months of follow-up in SIB arm, there was an improvement of the cosmesis with a majority of the patients showing excellent(59%) and good (34%) cosmetic score.
Conclusions
In a selected cohort of patients who have undergone breast conservation surgery, a simultaneous integrated boost along with WBI is considered equivalent radiobiological to sequential electron boost after WBI. This study reports better cosmetic outcomes and favourable toxicity profile with SIB compared to SEB over short-term follow-up which is statistically significant.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - A multicenter, prospective study of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer
Presenter: Yi-Hui Tang
Session: e-Poster Display Session
155P - Surgical outcomes and technical performance of robotic versus laparoscopic total gastrectomy for gastric cancer: A prospective comparative study FUGES-014
Presenter: Hua-Gen Wang
Session: e-Poster Display Session
156P - Safety and feasibility of laparoscopic spleen-preserving splenic hilar lymphadenectomy during total gastrectomy for advanced proximal gastric cancer: A randomized clinical trial
Presenter: Jian-Xian Lin
Session: e-Poster Display Session
157P - Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers
Presenter: Amy Prawira
Session: e-Poster Display Session
158P - A phase II study of trastuzumab with S-1 plus oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX study): Final report
Presenter: Atsuo Takashima
Session: e-Poster Display Session
159P - Open surgery can improve the 3-year postoperative survival in some patients with advanced gastric cancer compared with laparoscopic surgery: A multicenter, propensity score matching, in-depth analysis
Presenter: Ze-Ning Huang
Session: e-Poster Display Session
160P - Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Ning Li
Session: e-Poster Display Session
161P - Adjuvant tegafur/gimeracil/oteracil (S-1) versus platinum-based chemotherapies for resectable gastric cancer: Real-world experience and a propensity score matching analysis
Presenter: Chih Chieh Yen
Session: e-Poster Display Session
162P - Evaluation of neutrophil/lymphocyte ratio (NLR) in monitoring anastomotic leakage after radical total gastrectomy for gastric cancer
Presenter: Ru-Hong Tu
Session: e-Poster Display Session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session